One-capsule, once-daily dosing for adults with TD or HD chorea
See dosing for TARDIVE DYSKINESIA (TD)
See dosing for Huntington’s disease (hd) chorea
Only INGREZZA offers a
therapeutic dose from Day 11:
No other VMAT2 inhibitor can offer
the simplicity of INGREZZA1:
Why wait?
THERAPEUTIC DOSE FROM DAY 1
Why titrate?
No required titration
Why overcomplicate?
Start with INGREZZA
INGREZZA IS THE ONLY VMAT2 INHIBITOR TO OFFER A SPRINKLE FORMULATION1
Actor portrayal
GET YOUR PATIENTS STARTED ON INGREZZA RIGHT AWAY
Request samples of INGREZZA® (valbenazine) capsules today to start patients on treatment
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
DOSING FOR Tardive dyskinesia (TD)
DOSING FOR
Tardive dyskinesia
DOSING FOR Huntington’s disease (HD) chorea
DOSING FOR
HD chorea
Treat TD while preserving your patient’s antipsychotic regimen
Patients in the clinical trials were allowed to remain on their stable psychiatric treatment regimen1:
85%
took second-generation
antipsychotics
27%
took first-generation
antipsychotics
In KINECT 3, the most common types of concomitant medications were2,3:
- Antipsychotics (85.5%)
- Antidepressants (66.5%)
- Anticholinergics (37.0%)
- Antiepileptics (35.2%)
- Anxiolytics (27.7%)
- ACE inhibitors (25.1%)
The initial dosage for INGREZZA is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability.1
DRUG INTERACTIONS AND DOSING CONSIDERATIONS
The VMAT2 inhibitor with the most clinically informed dosing recommendations for drug interactions1
INGREZZA1
AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)8,a
STUDIED?
STUDIED?
Strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine)
STUDIED?
90% increase in exposure to active metabolite
Recommended dosage is 40 mg/day
STUDIED?
550% increase in exposure to active metabolite
Max dosage of 36 mg/day
INGREZZA1
AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)8,a
Poor CYP2D6 metabolizers
STUDIED?
90% increase in exposure to active metabolite
Recommended dosage is 40 mg/day
STUDIED?
Max dosage of 36 mg/day
INGREZZA1
AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)8,a
Strong CYP3A4 inhibitors
(eg, itraconazole, ketoconazole, clarithromycin)
STUDIED?
110% increase in exposure to active metabolite
Recommended dosage is 40 mg/day
STUDIED?
INGREZZA1
AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)8,a
Strong CYP3A4 inducers
(eg, rifampin, phenytoin, carbamazepine, St. John’s wort)
STUDIED?
NO ADDED SAFETYADDED SAFETY CONCERNS
80% decrease in exposure to active metabolite
Not recommended due to subtherapeutic exposure
STUDIED?
Dosing considerations do not imply differences in safety, efficacy, or clinical outcomes
aAUSTEDO® and AUSTEDO XR® are trademarks of Teva Pharmaceutical Industries Ltd.
DOSING CONSIDERATIONS FOR SPECIAL POPULATIONS
INGREZZA was studied and proven effective in the widest range of patients1,2
INGREZZA1
AUSTEDO® (deutetrabenazine) and AUSTEDO XR® (deutetrabenazine)8,b
STUDIED?
STUDIED?
Elderly Patients
(≥65 years)
STUDIED?
NO ADJUSTMENT REQUIRED*
STUDIED?
Dose selection should be cautious†
Renal impairment
STUDIED?
NO ADJUSTMENT REQUIRED
STUDIED?
Hepatic impairment
STUDIED?
40 mg once daily
MODERATE-SEVERE IMPAIRMENT
STUDIED?
Concomitant anticholinergics
(eg, benztropine)
STUDIED?
TD patients on anticholinergics INCLUDED in pivotal trial
STUDIED?
TD patients on anticholinergics EXCLUDED from pivotal trial
Dosing considerations do not imply differences in safety, efficacy, or clinical outcomes.
*The randomized, placebo-controlled study of INGREZZA in patients with chorea associated with Huntington's disease did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently from younger subjects.
†See deutetrabenazine prescribing information section 8.5.
‡See deutetrabenazine prescribing information section 12.3.
§See deutetrabenazine prescribing information section 8.6.
EXPLORE FINANCIAL ASSISTANCE OPTIONS
$10 or less out-of-pocket is what most patients pay for INGREZZA7
SAVINGS & SUPPORT§Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and the primary active metabolite of INGREZZA, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes.
REFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
- Data on file. Neurocrine Biosciences, Inc.
- Brar S, Vijan A, Scott FL, et al. Pharmacokinetic and pharmacologic characterization of the dihydrotetrabenazine isomers of deutetrabenazine and valbenazine. Clin Pharmacol Drug Dev. 2023;12(4):447-456.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
- Skor H, Smith EB, Loewen G, O’Brien CF, Grigoriadis DE, Bozigian H. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17(3):449-459.
- Measured by NDC; data on file as of Q3 2023. Neurocrine Biosciences, Inc.
- Deutetrabenazine [prescribing information]. Parsippany, NJ: Teva Pharmaceutical Industries Ltd.